Hongge Liang

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Cancer gene therapy

Thoracic cancer

OncoTargets and therapy

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Hongge Liang, Yan Xu, Jing Zhao, Minjiang Chen, Mengzhao Wang
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers. Cancer gene therapy (2024)
Hongge Liang, Yan Xu, Jing Zhao, Minjiang Chen, Mengzhao Wang
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers. Cancer gene therapy 31 (5) (2024)
Hongge Liang, Yan Xu, Jing Zhao, Minjiang Chen, Mengzhao Wang
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers. Cancer gene therapy 31 (5) (2024)
Hongge Liang, Yan Xu, Jing Zhao, Minjiang Chen, Mengzhao Wang
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers. Cancer gene therapy 31 (5) (2024)
Xiaoling Qiu, Hongge Liang, Wei Zhong, Jing Zhao, Min-Jiang Chen, Zhaohui Zhu, Yan Xu, Mengzhao Wang
Prognostic impact of maximum standardized uptake value on 18 F-FDG PET/CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study. Thoracic cancer 12 (6) (2021)
Hongge Liang, Yan Xu, Minjiang Chen, Wei Zhong, Mengzhao Wang, Jing Zhao
Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thoracic cancer 11 (4) (2020)
Hongge Liang, Mengzhao Wang
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. OncoTargets and therapy 13 (2020)
Hongge Liang, Di Ma, Yan Xu, Jing Zhao, Min-Jiang Chen, Xiaoyan Liu, Wei Zhong, Junling Li, Mengzhao Wang
Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. Cancer management and research 11 (2019)